Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Public ClinicalTrials.gov record NCT01995058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
Study identification
- NCT ID
- NCT01995058
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2014 (Type not available)
- Primary completion
- Nov 2014 (Actual)
- Completion
- Nov 2014 (Actual)
- Last update posted
- Jan 8, 2026
2014
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85258 | — |
| Not listed | Sedona | Arizona | 86336 | — |
| Not listed | Tucson | Arizona | 85710 | — |
| Not listed | Oxnard | California | 93030 | — |
| Not listed | San Diego | California | 92108 | — |
| Not listed | Aurora | Colorado | 80012 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Athens | Georgia | 30607 | — |
| Not listed | Atlanta | Georgia | 30318 | — |
| Not listed | Peoria | Illinois | 61615 | — |
| Not listed | Wichita | Kansas | 67214 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Tualatin | Oregon | 97062 | — |
| Not listed | Charleston | South Carolina | 29414 | — |
| Not listed | Greenville | South Carolina | 29605 | — |
| Not listed | Myrtle Beach | South Carolina | 29572 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01995058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01995058 live on ClinicalTrials.gov.